PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31054980-10	2019	CONCLUSION: We demonstrated for the first time that PNPLA3 CG+GG increase the risk of NAFLD among Brazilian subjects.	cysteinylglycine	59-61	patatin like phospholipase domain containing 3	Homo sapiens	52-58	
31527889-7	2019	PNPLA3 G allele increased the risk of LT for CLF in both allelic and recessive models (CG + GG vs. CC: OR, 1.90; 95% CI, 1.017-3.472, P = 0.045 and GG vs. CC + CG: OR, 2.94; 95% CI, 1.032-7.513, P = 0.042).	cysteinylglycine	87-89	patatin like phospholipase domain containing 3	Homo sapiens	0-6	
31527889-7	2019	PNPLA3 G allele increased the risk of LT for CLF in both allelic and recessive models (CG + GG vs. CC: OR, 1.90; 95% CI, 1.017-3.472, P = 0.045 and GG vs. CC + CG: OR, 2.94; 95% CI, 1.032-7.513, P = 0.042).	cysteinylglycine	160-162	patatin like phospholipase domain containing 3	Homo sapiens	0-6	
30738435-6	2019	The PNPLA3 I148M variant was significantly associated with the risk of NAFLD in an additive model (CG, OR = 2.092, 95% CI: 1.551-2.820, P = 0.000; GG, OR = 4.566, 95% CI: 3.141-6.638, P = 0.000, respectively).	cysteinylglycine	99-101	patatin like phospholipase domain containing 3	Homo sapiens	4-10	
30027138-6	2018	In addition, we found an association of the PNPLA3 rs738409 G allele with the presence of diabetes (22% versus 28% versus 58% for CC versus CG versus GG genotype, respectively; P = 0.02).	cysteinylglycine	140-142	patatin like phospholipase domain containing 3	Homo sapiens	44-50	
26379412-8	2015	De novo NAFLD was more frequent in PNPLA3 GG carriers (0.33 vs 0.10 for GG vs CC + CG carriers, P = 0.018), while the genetic impact on NAFLD susceptibility was insignificant when categorized by the TM6SF2 polymorphism (0.19 in CC vs 0.14 in CT + TT carriers, P = 0.883).	cysteinylglycine	83-85	patatin like phospholipase domain containing 3	Homo sapiens	35-41	
27862719-7	2017	RESULTS: Of 238 patients, PNPLA3 genotype frequencies were: CC, 0.14; CG, 0.46; and GG, 0.40.	cysteinylglycine	70-72	patatin like phospholipase domain containing 3	Homo sapiens	26-32	
28050235-5	2016	RESULTS: The PNPLA3 rs738409 genotype distribution for CC, CG and GG was 39.2%, 52.6% and 8.2%.	cysteinylglycine	59-61	patatin like phospholipase domain containing 3	Homo sapiens	13-19	
25713769-7	2015	RESULTS: PNPLA3 genotypes were CC, CG, and GG for 118, 72, and 41 patients, respectively.	cysteinylglycine	35-37	patatin like phospholipase domain containing 3	Homo sapiens	9-15	
25801076-7	2015	When stratifying for obesity, PNPLA3 was associated with NASH in non-obese patients only (12.0% in CC vs. 18.3% in CG vs. 27.3% in GG, P = 0.01), including after correction for metabolic confounders (OR 2.06, 95% CI 1.26-3.36, P = 0.004).	cysteinylglycine	115-117	patatin like phospholipase domain containing 3	Homo sapiens	30-36	
21745282-8	2011	Furthermore, there was a dose effect of the PNPLA3 I148M genotype, in that CG heterozygotes had a risk of NAFLD between CC and GG homozygotes [adjusted odds ratio (OR)=2.03, 95% confidence interval (CI)=1.23-3.375 for the GG genotype and adjusted OR=1.55, 95% CI=1.02-2.35 for the CG genotype].	cysteinylglycine	75-77	patatin like phospholipase domain containing 3	Homo sapiens	44-50	
23859071-3	2013	Recipient PNPLA-3 genotype was independently associated with obesity (BMI > 30) at 3 years posttransplant (genotype CC 33.7%, CG 48.3% and GG 82.4%, p = 0.002), with an odds ratio (OR 2.54, CI 1.38-4.66, p = 0.003), associated with the G allele.	cysteinylglycine	129-131	patatin like phospholipase domain containing 3	Homo sapiens	10-17	
21168155-7	2011	Variant PNPLA3 rs738409 genotypes were associated with increases in mean serum alanine aminotransferase level of 4.77 IU/L (P = .0435) in subjects with CG alleles and of 10.86 IU/L (P < .0001) in those with GG alleles compared with subjects with CC alleles.	cysteinylglycine	152-154	patatin like phospholipase domain containing 3	Homo sapiens	8-14